Gene G Olinger

InstitutionNational Institutes of Health
AddressFrederick
Maryland
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 5 Covid-19 publications, with a maximum of 2 publications in March 2021
    All Publications
    Bar chart showing 73 publications over 18 distinct years, with a maximum of 11 publications in 2015
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yeh KB, Scullion M, Michelotti JM, Olinger G. First Movers in Molecular Detection: Case Comparison on Harnessing Research and Development, Industry, and Entrepreneurship. Front Med (Lausanne). 2021; 8:639440. PMID: 33842501.
      Citations:    
    2. Herring S, Oda JM, Wagoner J, Kirchmeier D, O'Connor A, Nelson EA, Huang Q, Liang Y, DeWald LE, Johansen LM, Glass PJ, Olinger GG, Ianevski A, Aittokallio T, Paine MF, Fink SL, White JM, Polyak SJ. Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. Antimicrob Agents Chemother. 2021 03 18; 65(4). PMID: 33468464.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    3. Boudjelal M, Almajed F, Salman AM, Alharbi NK, Colangelo M, Michelotti JM, Olinger G, Baker M, Hill AVS, Alaskar A. COVID-19 vaccines: Global challenges and prospects forum recommendations. Int J Infect Dis. 2021 Apr; 105:448-451. PMID: 33652065.
      Citations: 2     Fields:    Translation:Humans
    4. Bruchez A, Sha K, Johnson J, Chen L, Stefani C, McConnell H, Gaucherand L, Prins R, Matreyek KA, Hume AJ, Mühlberger E, Schmidt EV, Olinger GG, Stuart LM, Lacy-Hulbert A. MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses. Science. 2020 10 09; 370(6513):241-247. PMID: 32855215.
      Citations: 21     Fields:    Translation:HumansCellsPHPublic Health
    5. Abdulla A, Wang B, Qian F, Kee T, Blasiak A, Ong YH, Hooi L, Parekh F, Soriano R, Olinger GG, Keppo J, Hardesty CL, Chow EK, Ho D, Ding X. Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention. Adv Ther (Weinh). 2020 Apr 16; 2000034. PMID: 32838027.
      Citations: 10     
    6. Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Hensley LE, Frieman MB, Jahrling PB. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs. 2017 Dec; 77(18):1935-1966. PMID: 29143192.
      Citations: 74     Fields:    Translation:HumansCells
    7. Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, Matsushita H, Liu Y, Postnikova EN, Ork BL, Glenn G, Flyer D, Defang G, Raviprakash K, Kochel T, Wang J, Nie W, Smith G, Hensley LE, Olinger GG, Kuhn JH, Holbrook MR, Johnson RF, Perlman S, Sullivan E, Frieman MB. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016 Feb 17; 8(326):326ra21. PMID: 26888429.
      Citations: 56     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    8. Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Paulty MH, Velasco J, Whaley KJ, Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR, Olinger GG, Baric RS, Hensley LE, Jahrling PB, Marasco WA. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology. 2016 03; 490:49-58. PMID: 26828465.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    9. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015 Jul 28; 6:7712. PMID: 26218507.
      Citations: 138     Fields:    Translation:HumansAnimalsCells
    10. Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015 Feb; 59(2):1088-99. PMID: 25487801.
      Citations: 162     Fields:    Translation:HumansCells
    11. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug; 58(8):4885-93. PMID: 24841273.
      Citations: 256     Fields:    Translation:HumansAnimalsCells
    12. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. Interferon-ß and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014 Mar; 95(Pt 3):571-577. PMID: 24323636.
      Citations: 100     Fields:    Translation:HumansAnimalsCells